A Phase 1/2 interventional study of Zilebesiran and Placebo in Mild to Moderate Hypertension, sponsored by Alnylam Pharmaceuticals. Completed at 3 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Alnylam Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Hypertension with a site in Japan — 11 open to participants now, 17 under way, 8 of them phase 3. Hypertension · Japan.
Among the 142 studies in Hypertension with a site in Japan, this one is the 105th largest by enrollment of the 125 interventional ones that give a count, is one of 5 that started in 2024, is one of 2 in phase 1/2, and was the 127th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →11 of the 142 studies in Hypertension with a site in Japan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Japan, United States, Argentina and 1 more country
Ages 18+
Innovent Biologics (Suzhou) Co. Ltd. · Sites in Japan
Ages 18–75
Novartis Pharmaceuticals · Sites in Japan
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Japan, United States, Singapore
Ages 18+
Alnylam Pharmaceuticals · Sites in Japan, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 50 · Phase 4 41
First in 2000; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 237 across the 125 interventional studies, 1,452 across the 17 observational. Of the 105 that completed or were terminated, 48 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 142 have an industry lead sponsor. The 10 most frequent:
Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
Alnylam Pharmaceuticals has 7 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertension with a site in Japan that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT05326230Otsuka Medical Devices Co., Ltd. JapanA Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO) | 2026-12 |
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 142 studies in Hypertension with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered a single dose of zilebesiran.
Drug: Zilebesiran
Participants will be administered a single dose of placebo.
Drug: Placebo
Zilebesiran administered by subcutaneous (SC) injection
Also known as: ALN-AGT01
Placebo administered by SC injection
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Time frame: Up to 12 months
Percent Change From Baseline in Serum Angiotensinogen (AGT) at Month 3 and Month 6
Time frame: Baseline and Month 3 and Month 6
Change From Baseline at Month 3 and Month 6 in 24-hour Mean SBP and DBP Assessed by ABPM
Time frame: Baseline and Month 3 and Month 6
Change From Baseline at Month 3 and Month 6 in SBP and DBP Assessed by OBP
Time frame: Baseline and Month 3 and Month 6
Maximum Plasma Concentration (Cmax) of Zilebesiran and Its Metabolite
Cmax is the highest concentration of zilebesiran in the plasma and metabolite after a dose is given.
Time frame: Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.
Time to Maximum Plasma Concentration (Tmax) of Zilebesiran and Its Metabolite
Tmax is the time it takes for zilebesiran to reach the Cmax after administration.
Time frame: Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.
Elimination Half-life (t1/2) of Zilebesiran and Its Metabolite
t½ is the time it takes for the concentration of the drug in the plasma to be reduced by 50%.
Time frame: Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.
Area Under the Curve (AUClast) of Zilebesiran and Its Metabolite
AUClast is the AUC from the time of dosing to the last measurable concentration of the drug.
Time frame: Predose and 30 minutes, 1, 2, 3, 4, 6, 8, 12, 16, 24 and 48 hours post-dose.
Pooled Urine PK (fe) of Zilebesiran and Its Metabolite
Time frame: Predose and 2 to 6, 6 to 12, and 12 to24 hours post-dose.
Participants with mild to moderate hypertension were enrolled at three (3) sites in Japan.
| Milestone | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo |
|---|---|---|---|
| Started | 12 | 12 | 12 |
| Completed | 11 | 11 | 12 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Milestone | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo |
|---|---|---|---|
| Started | 11 | 11 | 12 |
| Completed | 11 | 11 | 12 |
| Not completed | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
| Participants | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo |
|---|---|---|---|
| Treatment-emergent AEs, n (%) | 6 | 6 | 4 |
| Related Treatment-emergent AEs, n (%) | 0 | 1 | 1 |
| Treatment-emergent SAEs, n (%) | 0 | 0 | 0 |
| Severe Treatment-emergent AEs, n (%) | 0 | 0 | 0 |
| Treatment-emergent AEs Leading to Withdrawal from Study, n (%) | 0 | 0 | 0 |
| Death (any fatal SAE), n (%) | 0 | 0 | 0 |
| Percent Change | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo |
|---|---|---|---|
| Month 3 (% Change from Baseline) | -96.85 ± 1.45 | -96.85 ± 2.32 | 6.93 ± 21.93 |
| Month 6 (% Change from Baseline) | -95.36 ± 2.17 | -95.79 ± 3.21 | -2.74 ± 12.75 |
| mmHg | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo |
|---|---|---|---|
| Month 3 SBP (Change from Baseline) | -15.2 ± 9.0 | -17.8 ± 11.8 | 0.4 ± 7.8 |
| Month 6 SBP (Change from Baseline) | -12.6 ± 4.8 | -12.2 ± 11.7 | -6.5 ± 11.0 |
| Month 3 DBP (Change from Baseline) | -8.6 ± 6.0 | -9.2 ± 6.5 | 0.3 ± 5.3 |
| Month 6 DBP (Change from Baseline) | -7.1 ± 2.4 | -8.2 ± 6.0 | -3.9 ± 6.6 |
| mmHg | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo |
|---|---|---|---|
| Month 3 SBP (Change from Baseline) | -14.4 ± 21.0 | -14.4 ± 12.3 | 4.4 ± 5.0 |
| Month 6 SBP (Change from Baseline) | -10.3 ± 12.9 | -6.8 ± 9.6 | 1.2 ± 13.3 |
| Month 3 DBP (Change from Baseline) | -7.8 ± 10.4 | -7.4 ± 8.0 | 0.1 ± 5.2 |
| Month 6 DBP (Change from Baseline) | -4.5 ± 7.9 | -1.7 ± 6.8 | -2.2 ± 7.1 |
Cmax is the highest concentration of zilebesiran in the plasma and metabolite after a dose is given.
| nanograms per milliliter (ng/mL) | Zilebesiran 300 mg | Zilebesiran 600 mg |
|---|---|---|
| Zilebesiran Plasma PK | 1024 ± 53.5 | 2445 ± 42.4 |
| Metabolite [AS(N-1)3'] Plasma PK | 101.4 ± 72.1 | 288.2 ± 49.7 |
Tmax is the time it takes for zilebesiran to reach the Cmax after administration.
| Hours | Zilebesiran 300 mg | Zilebesiran 600 mg |
|---|---|---|
| Zilebesiran Plasma PK | 3.53 (1.00 to 12.0) | 6.00 (1.00 to 16.0) |
| Metabolite [AS(N-1)3'] Plasma PK | 8.01 (3.00 to 16.0) | 16.00 (4.00 to 16.0) |
t½ is the time it takes for the concentration of the drug in the plasma to be reduced by 50%.
| Hours | Zilebesiran 300 mg | Zilebesiran 600 mg |
|---|---|---|
| Zilebesiran Plasma PK | 5.83 ± 65.3 | 5.56 ± 36.9 |
| Metabolite [AS(N-1)3'] Plasma PK | 9.42 ± 120.8 | 5.48 ± 25.6 |
AUClast is the AUC from the time of dosing to the last measurable concentration of the drug.
| ng*h/mL | Zilebesiran 300 mg | Zilebesiran 600 mg |
|---|---|---|
| Zilebesiran Plasma PK | 16150 ± 43.5 | 41260 ± 32.2 |
| Metabolite [AS(N-1)3'] Plasma PK | 1587 ± 73.8 | 4906 ± 47.5 |
| Percent | Zilebesiran 300 mg | Zilebesiran 600 mg |
|---|---|---|
| Zilebesiran Urine PK | 23.62 ± 21.2 | 30.08 ± 16.1 |
| Metabolite [AS(N-1)3'] Urine PK | 2.68 ± 42.7 | 3.85 ± 28.3 |
Collected over Up to 12 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zilebesiran 300 mg | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Zilebesiran 600 mg | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Placebo | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Event | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo |
|---|---|---|---|
| InfluenzaInfections and infestations | 0/12 | 2/12 | 0/12 |
| PharyngitisInfections and infestations | 2/12 | 0/12 | 0/12 |
| HeadacheNervous system disorders | 2/12 | 1/12 | 0/12 |
| Eye pruritusEye disorders | 0/12 | 1/12 | 0/12 |
| GastralgiaGastrointestinal disorders | 0/12 | 0/12 | 1/12 |
| NauseaGastrointestinal disorders | 0/12 | 0/12 | 1/12 |
| COVID-19Infections and infestations | 1/12 | 0/12 | 1/12 |
| Alanine aminotrasferase increasedInvestigations | 1/12 | 0/12 | 0/12 |
| Blood alkaline phosphatase increasedInvestigations | 0/12 | 1/12 | 0/12 |
| Blood potassium increasedInvestigations | 0/12 | 1/12 | 0/12 |
Safety Analysis Set (SAS): All participants who received any amount of study drug. All by-treatment analyses based on the Safety Analysis Set were grouped according to the treatment actually received.
| Age, Categorical(Participants) | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo | Total |
|---|---|---|---|---|
| Age category (years), n (%) — <=18 years | 0 | 0 | 0 | 0 |
| Age category (years), n (%) — Between 18 and 65 years | 12 | 9 | 9 | 30 |
| Age category (years), n (%) — >=65 years | 0 | 3 | 3 | 6 |
| Age, Continuous(Years) | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo | Total |
|---|---|---|---|---|
| Median | 58.5 (20 to 64) | 54.5 (38 to 70) | 58.5 (50 to 66) | 58 (20 to 70) |
| Sex: Female, Male(Participants) | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo | Total |
|---|---|---|---|---|
| Sex (male or female), n (%) — Female | 6 | 5 | 1 | 12 |
| Sex (male or female), n (%) — Male | 6 | 7 | 11 | 24 |
| Race (NIH/OMB)(Participants) | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo | Total |
|---|---|---|---|---|
| Race, n (%) — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race, n (%) — Asian | 12 | 12 | 12 | 36 |
| Race, n (%) — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Race, n (%) — Black or African American | 0 | 0 | 0 | 0 |
| Race, n (%) — White | 0 | 0 | 0 | 0 |
| Race, n (%) — More than one race | 0 | 0 | 0 | 0 |
| Race, n (%) — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| 24-hour Mean Blood Pressure by Ambulatory Blood Pressure Monitoring (ABPM)(millimeters of mercury (mmHg)) | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo | Total |
|---|---|---|---|---|
| Baseline Systolic Blood Pressure (SBP; Actual) | 143.6 ± 12.2 | 138.9 ± 8.0 | 137.7 ± 6.8 | 140.1 ± 9.4 |
| Baseline Diastolic Blood Pressure (DBP; Actual) | 87.2 ± 8.2 | 86.6 ± 8.2 | 85.6 ± 5.4 | 86.4 ± 7.2 |
| Mean Office Blood Pressure (OBP)(mmHg) | Zilebesiran 300 mg | Zilebesiran 600 mg | Placebo | Total |
|---|---|---|---|---|
| Baseline SBP (Actual) | 139.8 ± 11.5 | 134.3 ± 9.4 | 133.9 ± 8.5 | 136 ± 10 |
| Baseline DBP (Actual) | 88.3 ± 7.4 | 86.6 ± 8.3 | 89.2 ± 6.3 | 88 ± 7.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Ran from Jun 2024 to primary completion in Jul 2025, 13 months.
Results were first posted in Apr 2026, 9 months after primary completion.
Of 21 phase 1/2 interventional studies under Hypertension, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 60. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zilebesiran